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5-year overall cost per patient was €13,900-€17,200 in Hungary, €16,300-€18,300 in
Poland, €8,900-€9,600 in Serbia and €12,500-€15,700 in Slovakia (presented in ranges
due to uncertainty around palliative care). Chemotherapy-associated costs ac-
counted for 59-71% of the total, followed by primary surgical treatment (13-23%)
and palliative care (4-15%). Contribution of drug costs to the overall costs varied
among the countries (in Poland 29%, in Serbia 55% of total costs). CONCLUSIONS:
Given the scarcity of OC cost studies worldwide, these findings may provide a
useful source for clinicians and decision makers in understanding the economic
implications of managing ovarian cancer in Central and Eastern Europe and the
need for innovative therapies.
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OBJECTIVES:Toexaminetheincrementalcostsofchemotherapy-associatedAEsinmBC
METHODS: The PharMetrics Database (2000-2010) was used to identify mBC pa-
tients treated with first- or second-line taxane (paclitaxel or docetaxel) or capecit-
abine-based regimens, with treatment episodes (TEs)30 days. Inverse probability
weighting was used to balance patient characteristics between cohorts with and
without AEs. Incremental costs attributable to AEs were assessed by comparing
costs incurred during TEs with and without AEs and included the following com-
ponents: inpatient, outpatient, emergency room, other medical service, pharmacy
costs, and total health care costs. Sensitivity analyses were conducted to examine
the average monthly costs in patients cohorts stratified by the number and type of
AEs reported during the TEs. RESULTS: 3,222 women (mean age57) received a first-
and/or second-line taxane or capecitabine for mBC. Of the 2,678 1st-line patients, 69.7%
received taxane and 30.3% capecitabine. AEs were commonly seen in patients treated
with first-line taxane (94.6%) and capecitabine (83.7%). On average, the total monthly
incremental cost associated with AEs was 38% higher ($3,547) for taxane and 9% higher
($854) for capecitabine. Inpatient and other drug costs accounted for a majority of the
increasedcosts.Of1,084second-linepatients,66.0%receivedtaxaneand34.0%withcape-
citabine.94.4%ofsecond-linetaxanepatientsand84%ofcapecitabinepatientshadanAE.
The average total monthly incremental cost associated with AEs for taxane was $5,320
and $4,933 for capecitabine (69.5% and 82.9% higher vs. patients without AEs). Differences
in pharmacy costs drove the incremental AE-related costs in taxanes users; inpatient and
outpatient costs accounted for the majority of these costs in capecitabine users. Sensitiv-
ity analyses showed a clear trend of an increasing economic burden with the number of
AEs. CONCLUSIONS: Chemotherapy-related AEs are associated with a substantial
economic burden primarily explained by increased inpatient, outpatient, and
pharmacy costs.
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There is some evidence that the annual number of patients diagnosed with anal
cancer in the UK is increasing. Such a rise could potentially have important health
and economic consequences. OBJECTIVES: To estimate hospital treatment costs
for anal cancer in England, based on data from the HES database, as part of a wider
study investigating the total economic burden of anal cancer in the UK.METHODS:
Inpatient admissions for anal cancer between the years 2006/07 to 2010/11 were
retrospectively analysed. Data was obtained from HES, a database covering English
hospital activity, with inpatient episodes aggregated into spells of care associated
with a specific Healthcare Resource Group (HRG). The HRGs were linked to costs
from the UK National Tariff in order to calculate the average annual and per inpa-
tient payments for treatment of anal cancer, as per the NHS Payment by Results
framework. Where necessary, costs were supplemented by expert opinion and
other published cost estimates. A limited amount of HES data on outpatient con-
sultations was also collected and analysed. RESULTS: In England, the average an-
nual payments for inpatient care associated with anal cancer are estimated to total
£7,754,219 (males  £2,930,360, females  £4,823,859). This translated to a mean
annual cost per inpatient of £4,605 and £5,232 for males and females respectively.
Outpatient costs were lower across both genders with annual payments for outpa-
tient care estimated at £184,479 for males and £286,686 for females. This is likely to
be a significant underestimate due to coverage issues with the HES outpatient
dataset on account of local variation in the sources of funding for certain treat-
ments. Further research into outpatient costs is currently ongoing.CONCLUSIONS:
Despite the significant underestimation of the outpatient costs, these results sug-
gest anal cancer places a significant health and economic burden on the English
NHS.
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OBJECTIVES: To assess the management and associated lifetime costs in MM pa-
tients as from the diagnosis of unresectable metastatic disease until death.
METHODS: A retrospective patient chart review was performed at the Antwerp
University Hospital to obtain data on medical consumption related to the manage-
ment of unresectable metastatic MM (umMM). A complete registry of all MM pa-
tients who visited the hospital between 2007 and May 2012 was compiled. Eligible
for this retrospective chart review were patients with umMM with sufficient data
available and who deceased before May 2012. Data on demographics, disease char-
acteristics and management of umMM were collected. Direct costs were calculated
by multiplying each item of resource use with its unit cost (2012, € ) using the
Belgian public health care payer’s perspective (PHCP) and patient’s perspective.
Average (bootstrap 95%CI) overall costs per patient were calculated. RESULTS: Out
of 148 registered MM patients, 29 were eligible and included in this chart review.
The median overall survival time in all patients was 6.0 months. 86% (n25) of
patients were treated by systemic treatment(s) of which 24% (n6) received up to 4
different treatment lines. Dacarbazine was administered in all patients as a single
agent or in combination therapy. 4 patients received 1 to 4 cycles of ipilimumab
treatment. 53 (43%) of the 123 hospitalizations were for chemotherapy administra-
tion. The mean overall cost per patient was €31,637 (bootstrap 95% CI:23,993-
39,891), of which € 30,585 € (95%CI: 23,154-38,784) was reimbursed. The PHCP cost
was driven by hospitalization costs and systemic treatments costs both represent-
ing 33% of total cost. CONCLUSIONS:Management of umMM result in considerable
costs for the PHCP mainly driven by systemic treatment costs and hospitalization
costs. It would be interesting to extend this study in a broader population.
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OBJECTIVES: This review was conducted to assess the economic burden of pancre-
atic cancer (PC) in Europe. METHODS: Systematic search of Embase® and MED-
LINE® databases was conducted from January 2002 to June 2012 to identify eco-
nomic studies on PC in Europe. English language studies, regardless of design and
intervention were included. Eligibility of trials was assessed by two reviewers with
any discrepancy reconciled by a third, independent reviewer. RESULTS: Of the 97
retrieved citations, seven met pre-defined inclusion criteria. Four studies were
cost-analyses while other three were cost-minimisation, cost-utility, and cost-ben-
efit analysis, respectively. In Europe, the predicted PC mortality varied between
6.6-8.2/100,000 men and between 4-5.7/100,000 women in 2012. In Sweden, the
direct costs/patient/month associated with PC rose from €1578 in 2001 to €3103 in
2002-2005 and then to €6590 in 2009. In 2009, the major contributors of this direct
cost were hospitalisations (€4670), surgery (€719), and chemotherapy (€258). The
mean total cost of illness/patient for PC in Germany was €31,375 (cost years 2000-
2003), where direct cost was responsible for 90% of this total value and the remain-
ing 10% was contributed by indirect costs including loss of productivity due to
days-off work. In 2009, the estimated cost/patient associated with loss of produc-
tivity due to absenteeism was €6077 in Sweden. Upon assessment of curative re-
section cost for PC per patient in Sweden, it was found to be about €39,000 in 2009.
The mean costs per patient associated with the use of diagnosis of PC were $1925 in
Switzerland (2004), $1249 in Spain (2001), and €1545 in Sweden (2001).
CONCLUSIONS: Although limited data is available, a trend in increase of fiscal
burden of PC was observed. The major contributors of this burden were surgery,
hospitalisations, chemotherapy, and loss of productivity. Therapies that prevent or
delay disease progression could reduce this burden.
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OBJECTIVES: Chronic lymphocytic leukemia (CLL) is a slowly progressing but mor-
tal disease that imposes a high economic burden on sickness funds and society.
The objective of this study is to analyze and compare the direct and indirect costs
of CLL in Germany from the perspective of both sickness funds and society, and to
analyze the burden of the disease. METHODS: Using a database of 7.6 million
enrolled individuals, we identified 4198 CLL patients in 2007 and 2008. Costs attrib-
utable to CLL were estimated using a case-control design, with a control group of
150 individuals randomly drawn by age and sex for each CLL observation. We used
GEE and count data models to test for differences in costs and health care
utilization. RESULTS: The cost attributable to CLL per prevalent case amounts to
€4946 from the payer’s perspective, and €7910 from that of society. Inpatient stays
and pharmaceutical consumption are the main cost drivers of the disease. The
burden of disease in Germany is estimated to be approximately €201 million per
year from the sickness fund perspective (€322 million from the societal
perspective). CONCLUSIONS: Compared with common diseases such as diabetes
or COPD, the economic burden of CLL is considerably lower. However, the cost of
treatment per case is about twice as high as for these common diseases, even
though treatment is performed in later stages only. Owing to new health care
technologies, an ageing population, and an increasing incidence, it is likely that the
burden of the disease will continue to grow.
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The number of cases of head and neck (H&N) cancer diagnosed in the UK has been
increasing in recent years. These cancers often require complex surgical treat-
ments and extensive rehabilitation. OBJECTIVES: To use data from the Hospital
Episode Statistics (HES) database to estimate the costs incurred by English NHS
hospitals due to treatment of H&N cancers, with a particular focus on oral cavity,
oropharyngeal and laryngeal cancers. METHODS: Inpatient admissions for H&N
cancer between the years 2006/07 to 2010/11 were retrospectively analysed. Data
was obtained from HES, a database covering English hospital activity, with inpa-
tient episodes aggregated into spells of care associated with a specific Healthcare
Resource Group (HRG). The HRGs were linked to costs from the UK National Tariff
in order to calculate the average annual and per patient payments for inpatient
treatment of H&N cancer, as per the NHS Payment by Results framework. Where
necessary, costs were supplemented by expert opinion and other published cost
estimates. RESULTS: Payments to NHS hospitals in England for inpatient stays due
to H&N cancer are estimated to cost on average £57.1 million per year. The main
driver of costs are the disproportionately high number of male cases, the costs of
which are £12,517,235, £13,327,351 and £16,185,743 for oral cavity, oropharyngeal
and laryngeal cancer, respectively. This translates to respective inpatient costs per
male of £5,354, £6,926, and £6,693. Despite similar costs per female inpatient, the
average annual payments for inpatient care were approximately £7,579,905,
£4,337,947 and £3,166,535, for oral cavity, oropharyngeal and laryngeal cancers.
CONCLUSIONS: Based on inpatient treatment alone, H&N cancers place a signifi-
cant economic burden on English NHS hospitals. This, however, is far less than the
total burden of treatment as a large proportion is delivered in the outpatient set-
ting. Further research is currently underway to quantify this total burden.
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OBJECTIVES: To estimate the costs associated with prostate cancer (PC) for Russia
in 2009. METHODS: We used the standard cost of illness (COI) method, relying on
the prevalence approach and adopting the viewpoint of the payers (national and
regional governments). We calculated direct medical costs (hospital and outpatient
services and drugs provided in outpatient care), non-medical costs (monetary pay-
ments in social benefits) and indirect costs (projected productivity loss due to
sickness and disability) associated with the PC in Russia in 2009. The data for
analysis was obtained from the national statistics, regional cancer and prescription
registries, expert panel interviews and literature. The costs were calculated for the
total population of PC patients in Russia. To calculate direct medical costs, we used
national reimbursement rates per unit of care (1 hospital day or 1 visit to an out-
patient oncology clinic) and regional data on prostate cancer drug costs. To access
non-medical costs, we used data on social benefits expenditures. Indirect costs
were estimated with friction costs method. RESULTS: The total costs of prostate
cancer in Russia in 2009 was 3,674 billion RUR (€89,98 mln), or 33 270 RUR (€814) as
average cost per patient per year. More than half of total cost (65,4%) occur in
patients during the 1st year after diagnosis. The direct medical costs accounted for
73,1% of total spending, direct non-medical costs – for 19,7%, and indirect costs – for
7,17%. Direct medical costs represented 86,6% of total spending in PC patients
within the 1st years after the diagnosis; during the subsequent years after the
diagnosis this number reduces to 47,8%. CONCLUSIONS: Our analysis demon-
strates that the most significant part of spending in prostate cancer overall is
related to direct medical costs during the 1st year after the diagnosis.
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OBJECTIVES:With current and increasing pressures to limit expenditure for health
care provision in many countries, a better understanding of the cost burden of
colorectal cancer (CRC), as well as specific determinants and drivers of expenditure
is needed. Cost estimates for individual patients vary widely, according to the data
source. Cost-of-illness (COI) studies are a useful tool to analyse and critically eval-
uate cost aspects of colorectal cancer. METHODS: A systematic review was con-
ducted from 2002 to 2012 to identify COI studies related to colorectal cancer,
searching the Medline, PubMed, Science Direct, Cochrane Library and the York CRD
databases. The search was in line with PRISMA guidelines. Studies that used prev-
alence-based approaches were grouped separately from those studies reporting
incidence-based estimates. RESULTS: Of the total of 11 studies, 6 studies reported
prevalence-based estimates, and 5 studies focused on incidence-based data. In the
studies included in the review, long term costs for colorectal cancer of up to 50,175$
per patient (2008 values) have been estimated. Most studies in the review have
shown that the initial and terminal phases of colorectal cancer care are the most
expensive, with the least costly phase for continuing treatment. However, one
study also highlighted that stage I CRC disease was the least costly, with stage III
the most costly of all four stages, due to the high cost impact of biological agents.
CONCLUSIONS: COI studies in colorectal cancer can identify specific components
and areas of care that are especially costly, thereby establishing attention for more
cost-effective approaches, especially relevant to the increased use of biological
agents in the field of personalized medicine. Future cost-of-illness studies would
greatly benefit from common approaches to methodology, concerning study de-
sign, description and cost component data. COI studies are an important tool for
HTA and especially health economic evaluations of personalized medicine.
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OBJECTIVES: Understand treatment patterns and quantify resource utilization of
HR HER2– ABC, with the overall aim of comparing costs and disease burden as
patients progress from hormonal therapy (HT) to chemotherapy (CT). METHODS:
Chart audit in France, Germany, The Netherlands, Belgium, and Sweden of 375
living and deceased postmenopausal female patients diagnosed with estrogen-
and/or progesterone-receptor–positive HER2– ABC in the past 4 years. Patients
were required to have progressed on 1 line of prior HT in the adjuvant or ad-
vanced setting and to have completed1 line of CT treatment (2 full cycles) in the
ABC setting. The chart audit was completed online using a standardized form
developed with the assistance of European academic physicians, pharmacy direc-
tors, and hospital administrators. Participation was sought from 12-21 oncologists
per country, except in Germany (11 oncologists and 10 gynecologists to reflect local
clinical practice). Data collection complied with European and country market re-
search regulations. RESULTS: Preliminary analyses included 265 charts (80% of
patients between 40 and 69 years of age) with one-third having de novo ABC, one-
third progressing during or within 1 year of adjuvant therapy, and one-third being
late progressors. In the first-line ABC setting, 57% received HT (nearly 90% pro-
gressed to CT in second-line), 43% CT, and 15% also targeted therapy (mostly bev-
acizumab). The switch from HT to CT was associated with a marked increase in
resource utilization and associated costs. Besides drug acquisition and administra-
tion costs, the main CT cost drivers were management for major CT side effects
(low blood cell counts, febrile neutropenia, neurotoxicity, mucositis) and side-ef-
fect–related hospitalization events (14% and 7% of all hospitalization events in
first- and second-line CT, respectively). CONCLUSIONS: Our results highlight the
increased costs and disease burden for postmenopausal HR HER2– ABC patients
treated with CT versus HT in EU countries.
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OBJECTIVES:Bevacizumab, a humanized monoclonal IgG antibody against the vas-
cular endothelial growth factor (VEGF), is reimbursed in the Czech Republic in
combination with chemotherapy for the first-line treatment of patients with met-
astatic colorectal cancer (mCRC). However, its high cost is a potentially limiting
factor. METHODS: The cost and effectiveness of bevacizumab in the real clinical
practice was retrospectively evaluated in the National comprehensive cancer cen-
ter from the perspective of health care payer. Cost data (examination, medication,
hospitalization) were collected since the initiation of bevacizumab treatment to
any tumor response (RECIST criteria - Complete Response (CR), Partial Response
(PR), Stable Disease (SD), Progressive Disease (PD)) and/or to death. Minimal fol-
low-up for all patients was 12 months. Costs were valued in CZK and converted to
EUR (€1CZK 25.78). RESULTS:A total of 218 patients with mCRC were treated with
bevacizumab in the first line treatment (132 men (60.6%); mean age 58.3 years)
between 11/2005-12/2010. The most frequent chemotherapeutic regimens were:
XELOX (55%), FOLFOX (26%), and FOLFIRI (4%). The treatment was mostly discon-
tinued due to PD (59% patients); further due to SD, PR or CR (total 8.3% patients),
adverse events (7.8% patients), surgery (5.5% patients). During our follow-up period
PD was recorded in 89% patients; 66% patients died. The mean cost per progres-
sion-free survival (median 9.1 months) was EUR 38,870.3 (CZK 1,002,076.3); the
mean cost to response PR, CR or SD was EUR 42,894.6 (CZK 1,105,823.1) after median
9.8 months of treatment. The median overall survival was 16.9 months and the
mean cost since initiation of treatment to death was EUR 50,791.3 (CZK 1,309,400.8).
CONCLUSIONS: The reimbursement of medication was the main cost driver ob-
served in our analysis. Drugs made up more than 93% to PR, CR or SD, 91% to PD and
88% to death of the total cost per patient respectively.
PCN61
MELODY BRAZIL – RESOURCE USE AND ASSOCIATED COSTS WITH
METASTATIC MELANOMA IN BRAZILIAN HEALTH CARE SYSTEM
Stefani SD1, Nita ME2, Nunes J3, Campos E4, Schmerling RA5, Barrios C6, Dzik C7, Alves
JS2, Johnston K8, Donato BMK9
1Hospital Mãe de Deus, Porto Alegre, RS, Brazil, 2Bristol-Myers Squibb S/A, São Paulo, SP, Brazil,
3Hospital Cancer Barretos, Barretos, Brazil, 4Univille (Universidade da Região de Joinville),
Joinville, Brazil, 5Hospital São José – Beneficência Portuguesa de São Paulo, São Paulo, Brazil,
6School of Medicine, Pontifical University Catholic RS, Porto Alegre, Brazil, 7Hospital Sirio
Libanes, Sao Paulo, Brazil, 8Oxford Outcomes, Vancouver, BC, Canada, 9Bristol-Myers Squibb
Company, Wallingford, CT, USA
OBJECTIVES: To characterize resource utilization and associated costs of patients
receiving systemic therapy outside of a clinical trial for unresectable stage III and IV
metastatic melanoma in Brazilian Healthcare System, and to compare results
across the public and private health systems.METHODS:A retrospective study was
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